The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: A systematic review

Bone Marrow Transplantation

Volumn 39, Issue 12, 2007, Pages 729-735

  Franchini, M ^a   Veneri, D ^b   Lippi, G ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTINEOPLASTIC AGENT; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; BLEEDING DISORDER; BONE MARROW TRANSPLANTATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DATA BASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HUMAN; LUNG EMBOLISM; LUNG HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

BLOOD COAGULATION; BONE MARROW TRANSPLANTATION; FACTOR VII; HEMORRHAGE; HUMANS; LEUKEMIA; RECOMBINANT PROTEINS;

EID: 34250183735     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705670     Document Type: Review

References (49)

1. Nègrier C, Lienhart A. Overall experience with Novoseven®. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): 19-24.
2. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408-413.
3. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-124.
4. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-1035.
5. Uhlmann EJ, Eby CS. Recombinant activated factor VIII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004; 11 198-204.
6. Ghorashian S, Hunt BJ. 'Off-license' use of recombinant activated factor VII. Blood Rev 2004; 18: 245-259.
7. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3864.
8. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 41: 431-439.
9. Franchini M, Lippi G, Franchi M. The use of recombinant activated FVII in obstetrical and gynaecological haemorrhage. Br J Obstet Gynaecol 2007; 114: 8-15.
10. Olajide O, Henke D, Gabriel DA. Hemorrhagic complications in bone marrow transplant: Possible roles of recombinant activated coagulation factor VII. TATM 2006; 8 (Suppl 1): 27-34.
11. Pihusch M. Bleeding complications after hemopoietic stem cell transplantation. Semin Hematol 2004; 41 (Suppl 1): 93-100.
12. Bacigalupo A. Hemopoietic stem cell transplants: The impact of haemorrhagic complications. Blood Rev 2003; 17: S6-S10.
13. White B, Martin M, Kelleher S, Browne P, McCann SR, Smith OP. Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukemia and acquired FVII deficiency. Br J Haematol 1999; 106 204-205.
14. Vidarsson B, Onundarson P. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83: 634-635.
15. Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant factor VIIa (NovoSeven) in a patient with FXI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551-553.
16. Geroftziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69: 219-222.
17. Prasad M, Winter SS, Frost JD, Hanrahan J, Schwartz M, Jones JE. Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases. J Pediatr Hematol/Oncol 2003; 25: 499-502.
18. Zulfikar B, Kayran SM. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004; 15: 261-263.
19. Osborne W, Bhandari S, Tait RC, Franklin IM. Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. Clin Lab Haematol 2004; 26: 229-231.
20. Udvardy M, Telek B, Mezey G, Batar P, Altorjay I. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patients with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer). Blood Coagul Fibrinolysis 2004; 15: 265-267.
21. Zver S, Andoljsek D, Cerneic P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patients with acute promyelocytic leukaemia. Eur J Haematol 2004; 72: 455-456.
22. Sallah S, Husain A, Nguyen P. Recombinant activated factor VII in patients with cancer and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004; 15: 577-582.
23. De Fabritiis P, Dentamaro T, Picardi A, Cudillo L, Masi M, Amadori S. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89 243-245.
24. Cervera JS, Mena-Duran AV, Piqueras CS. The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost 2005; 93: 383-384.
25. Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O. Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis 2005; 16: 145-147.
26. André JM, Galambrun C, Trzeciak MC, Dargaud Y, Kaplan-Gouet C, Jallu V et al. Acquired Glanzmann's thromboasthenia asociated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005; 27: 554-557.
27. Brenner B, Hoffman R, Balashov D, Shutluko E, Culic S, Nizamoutdinova E. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: An audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb/Hemost 2005; 1: 401-410.
28. Veneri D, Franchini M. Successful treatment of intestinal hemorrhage in an Jehovah's witness patient. Am J Hematol 2005; 79: 343-345.
29. Millar CG, Stringer MD, Sugarman I, Richards M. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171-174.
30. Das P, Carcao M, Hitzler J. Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. Pediatr Blood Cancer 2006; 47: 206-209.
31. Erikci AA, Ozturk A, Sayan O. Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia. Blood Coagul Fibrinolysis 2006; 17: 323-324.
32. Ucar C, Caliskan U. Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. Pediatr Hematol Oncol 2006; 23: 339-345.
33. Culic S, Kuljis D, Armanda V, Jankovic S. Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins. Pediatr Blood Cancer 2006 [E-pub ahead of print].
34. Mantzios G, Tsirigotis P, Pappa V, Spirou K, Giannopoulou V, Kaitsa I et al. Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding. Eur J Haematol 2007; 78: 173-174.
35. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405-407.
36. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975-978.
37. Hoffman R, Eliakim R, Zuckerman T, Rowe JM, Brenner B. Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukemia. J Thromb Haemost 2003; 1: 606-608.
38. Culligan DJ, Salamat A, Tait J, Westland G, Watson HG. Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Bone Marrow Transplant 2003; 31: 1183-1184.
39. Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation. Chest 2003; 124: 2400-2403.
40. Ippoliti C, Hey D, Donato ML. Use of activated recombinant factor VII for treatment of pulmonary hemorrhage in stem cell transplantation recipients. Proc Am Soc Clin Oncol 2003; 22: 841.
41. Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, Ahmad E. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa after allogeneic bone marrow transplantation. J Thromb Haemost 2004; 2: 1853-1855.
42. Henke D, Falk RJ, Gabriel DA. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004; 140 493-494.
43. Aneel AA, Gabriel DA, James LG, Nigel SK. Pilot study to test the efficacy and safety of Recombinant Factor VIIa (rFVIIa, NovoSeven) in the treatment of refractory hemorrhagic cystitis following high dose chemotherapy (Abstract). Blood 2004; 104: 1136.
44. Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L et al. F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935-1944.
45. Eller P, Pechlaner C, Wiedermann CJ. Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow-transplantation-related-gastrointestinal bleeding. Thromb J 2006; 4: 1.
46. Hoffman M, Monroe III DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6-9.
47. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-1139.
48. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212.
49. Pihusch R, Salat C, Schimdt E, Gohring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309.